COVID-19 Vaccination Before Initiating Rituximab Treatment Induces Strong Serological Response in Autoimmune Rheumatic Disease, Reducing Post-Pandemic Concerns About the Impact of Rituximab.

Autor: Ammitzbøll C; Aarhus University Hospital and Aarhus University, Aarhus, Denmark., Thomsen MK; Aarhus University Hospital and Aarhus University, Aarhus, Denmark., Bartels LE; Aarhus University Hospital, Aarhus, Denmark., Hansen CB; Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark., Hermansen MF; Aarhus University Hospital, Aarhus, Denmark., Hänel M; Aarhus University Hospital and Aarhus University, Aarhus, Denmark., Klose-Jensen R; Aarhus University Hospital, Aarhus, Denmark., Larsen ML; Aarhus University Hospital and Aarhus University, Aarhus, Denmark., Lauritsen MO; Aarhus University Hospital, Aarhus, Denmark., Mistegaard CE; Aarhus University Hospital and Aarhus University, Aarhus, Denmark., Mikkelsen S; Aarhus University Hospital, Aarhus, Denmark., Olesen JBM; Aarhus University Hospital, Aarhus, Denmark., Næser EU; Aarhus University Hospital, Aarhus, Denmark., Nielsen MA; Aarhus University Hospital, Aarhus, Denmark., Erikstrup C; Aarhus University Hospital and Aarhus University, Aarhus, Denmark., Garred P; Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark., Hauge EM; Aarhus University Hospital and Aarhus University, Aarhus, Denmark., Troldborg A; Aarhus University Hospital and Aarhus University, Aarhus, Denmark.

Publikováno v: ACR open rheumatology [ACR Open Rheumatol] 2024 Aug; Vol. 6 (8), pp. 519-528. Date of Electronic Publication: 2024 Jun 23.

Outcomes following SARS-CoV-2 infection in individuals with and without inflammatory rheumatic diseases: a Danish nationwide cohort study.

Autor: Svensson ALL; Department of Rheumatology, Center for Rheumatology and Spine Diseases, Rigshospitalet HovedOrtoCentret, Kobenhavn, Denmark annemarie.lyng.svensson.01@regionh.dk., Emborg HD; Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Kobenhavn, Denmark., Bartels LE; Rheumatology, Aarhus University Hospital, Aarhus N, Denmark., Ellingsen T; Rheumatology, Odense University Hospital, Odense, Denmark., Adelsten T; Department of Rheumatology, Sjællands Universitetshospital Køge, Koge, Denmark., Cordtz R; Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark.; Department of Rheumatology, Gentofte Hospital, Hellerup, Denmark., Dreyer L; Department of Rheumatology and Clinical Medicine, Aalborg University Hospital, Aalborg, Denmark.; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark., Obel N; Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Kobenhavn, Denmark.; Department of Infectious Diseases, Copenhagen University Hospital, Kobenhavn, Denmark.

Publikováno v: Annals of the rheumatic diseases [Ann Rheum Dis] 2023 Oct; Vol. 82 (10), pp. 1359-1367. Date of Electronic Publication: 2023 Jul 06.

Time Since Rituximab Treatment Is Essential for Developing a Humoral Response to COVID-19 mRNA Vaccines in Patients With Rheumatic Diseases.

Autor: Troldborg A; A. Troldborg, MD, PhD, Department of Rheumatology, Aarhus University Hospital, Department of Biomedicine, and Department of Clinical Medicine, Aarhus University; annetrol@rm.dk., Thomsen MK; M.K. Thomsen, MD, Department of Clinical Medicine, Aarhus University, and Department of Clinical Microbiology, Aarhus University Hospital., Bartels LE; L.E. Bartels, MD, PhD, J.B. Andersen, MD, A.D. Johannsen, MD, M.L.F. Hermansen, MD, PhD, Department of Rheumatology, Aarhus University Hospital., Andersen JB; L.E. Bartels, MD, PhD, J.B. Andersen, MD, A.D. Johannsen, MD, M.L.F. Hermansen, MD, PhD, Department of Rheumatology, Aarhus University Hospital., Vils SR; S.R. Vils MS, Department of Rheumatology, Aarhus University Hospital, and Department of Biomedicine, Aarhus University., Mistegaard CE; C.E. Mistegaard, MD, Department of Rheumatology, and Department of Clinical Microbiology, Aarhus University Hospital, and Department of Biomedicine, Aarhus University., Johannsen AD; L.E. Bartels, MD, PhD, J.B. Andersen, MD, A.D. Johannsen, MD, M.L.F. Hermansen, MD, PhD, Department of Rheumatology, Aarhus University Hospital., Hermansen MF; L.E. Bartels, MD, PhD, J.B. Andersen, MD, A.D. Johannsen, MD, M.L.F. Hermansen, MD, PhD, Department of Rheumatology, Aarhus University Hospital., Mikkelsen S; S. Mikkelsen, MD, Department of Clinical Immunology, Aarhus University Hospital., Erikstrup C; C. Erikstrup, MD, PhD, Department of Clinical Medicine, Aarhus University, and Department of Clinical Immunology, Aarhus University Hospital., Hauge EM; E.M. Hauge, MD, PhD, C. Ammitzbøll, MD, PhD, Department of Rheumatology, Aarhus University Hospital, and Department of Clinical Medicine, Aarhus University, Aarhus, Denmark., Ammitzbøll C; E.M. Hauge, MD, PhD, C. Ammitzbøll, MD, PhD, Department of Rheumatology, Aarhus University Hospital, and Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.

Publikováno v: The Journal of rheumatology [J Rheumatol] 2022 Jun; Vol. 49 (6), pp. 644-649. Date of Electronic Publication: 2022 Mar 01.

Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritis.

Autor: Bartels LE; Department of Rheumatology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 59, Entrance E, 8200, Aarhus, Denmark., Ammitzbøll C; Department of Rheumatology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 59, Entrance E, 8200, Aarhus, Denmark. chramm@rm.dk.; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. chramm@rm.dk., Andersen JB; Department of Rheumatology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 59, Entrance E, 8200, Aarhus, Denmark., Vils SR; Department of Rheumatology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 59, Entrance E, 8200, Aarhus, Denmark.; Department of Biomedicine, Aarhus University, Aarhus, Denmark., Mistegaard CE; Department of Rheumatology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 59, Entrance E, 8200, Aarhus, Denmark.; Department of Biomedicine, Aarhus University, Aarhus, Denmark.; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark., Johannsen AD; Department of Rheumatology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 59, Entrance E, 8200, Aarhus, Denmark., Hermansen MF; Department of Rheumatology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 59, Entrance E, 8200, Aarhus, Denmark., Thomsen MK; Department of Clinical Microbiology, Aarhus University Hospital, Aarhus, Denmark.; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark., Erikstrup C; Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark.; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark., Hauge EM; Department of Rheumatology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 59, Entrance E, 8200, Aarhus, Denmark.; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark., Troldborg A; Department of Rheumatology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 59, Entrance E, 8200, Aarhus, Denmark.; Department of Biomedicine, Aarhus University, Aarhus, Denmark.; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.

Publikováno v: Rheumatology international [Rheumatol Int] 2021 Nov; Vol. 41 (11), pp. 1925-1931. Date of Electronic Publication: 2021 Sep 02.

Immune checkpoint inhibitor-induced myocarditis in cancer patients: a case report and review of reported cases.

Autor: Matzen E; Department of Oncology, Aarhus University Hospital, Palle Juul-Jensens, Boulevard 99, 8200, Aarhus N, Denmark., Bartels LE; Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark., Løgstrup B; Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark., Horskær S; Department of Pathology, Aarhus University Hospital, Aarhus, Denmark., Stilling C; Department of Pathology, Aarhus University Hospital, Aarhus, Denmark., Donskov F; Department of Oncology, Aarhus University Hospital, Palle Juul-Jensens, Boulevard 99, 8200, Aarhus N, Denmark. fd@oncology.au.dk.

Publikováno v: Cardio-oncology (London, England) [Cardiooncology] 2021 Aug 09; Vol. 7 (1), pp. 27. Date of Electronic Publication: 2021 Aug 09.